Considerations for transplantation in the era of newer therapies for the treatment of hereditary ATTR amyloidosis.
The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.
Expert clinicians elaborate on key trial data revealed through the APOLLO and NEURO-TTR studies in hereditary ATTR amyloidosis.
A historical overview of the treatment of hereditary ATTR amyloidosis and considerations for using newer therapies such as patisiran or inotersen in appropriate patients.
Insight regarding the relationship between amyloid deposition and its impact on the gastrointestinal tract.
Recommendations for gene panel testing with genetic counseling to evaluate and manage patients with hereditary ATTR amyloidosis.
The director of the Pediatric Stroke Program at CHOP discussed the findings of a single-center study exploring the incidence of children presenting with acute arterial ischemic stroke who may have been eligible for mechanical thrombectomy.
The associate professor of neurology at Mayo Clinic spoke about the findings of a population-based cohort study seeking to investigate the incidence of levodopa-induced dyskinesia in atypical parkinsonism.
SAP Partner Banner